Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aztreonam Clear all
Recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

NCT06462235
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 39 Weeks
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis

NCT00805025
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 7, 2026, 3:15 AM EDT
Active, not recruiting Phase 2 Interventional

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

NCT03078010
View directory record Official record
Conditions
Intestinal Microbiome, Febrile Neutropenia
Interventions
Piperacillin-tazobactam, cefepime
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

NCT00757237
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tuscon, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2011 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Phase 4 Interventional Results available

The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas

NCT03158116
View directory record Official record
Conditions
Tracheostomy Infection
Interventions
Inhaled Aztreonam
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
7 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01314716
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

NCT01059565
View directory record Official record
Conditions
Cystic Fibrosis, Burkholderia Infections
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

NCT01055847
View directory record Official record
Conditions
Cystic Fibrosis, CF, Lung Infection, Pseudomonas Aeruginosa
Interventions
Aztreonam for Inhalation (AI), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

NCT02168816
View directory record Official record
Conditions
Osteomyelitis
Interventions
Intravenous Antibacterial Agent, Oral Antibacterial Agent
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational

Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study

NCT02179710
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Adherence dashboard motivational interviewing
Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

NCT03978091
View directory record Official record
Conditions
Bacterial Infection
Interventions
AZACTAM, Ceftazidime-Avibactam
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

NCT02449031
View directory record Official record
Conditions
Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions
TOBI® PODHALER®, TOBI®, Bethkis®, Cayston®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Bellflower, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting Phase 1 Interventional

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

NCT05777603
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
aerosolized aztreonam, aerosolized vancomycin, pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00104520
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Aztreonam for Pharyngeal Gonorrhea

NCT03867734
View directory record Official record
Conditions
Gonorrhea of Pharynx, Gonorrhea
Interventions
Aztreonam
Drug
Lead sponsor
University of Washington
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

NCT03137173
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
ceftobiprole medocaril, vancomycin+aztreonam
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

NCT03580044
View directory record Official record
Conditions
Serious Bacterial Infection
Interventions
ATM-AVI, BAT
Combination Product · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01984684
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions
delafloxacin, vancomycin, aztreonam
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational

Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution

NCT01736839
View directory record Official record
Conditions
Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 7, 2026, 3:15 AM EDT